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Abstract A revolution in chemical pathology occurred about 40
years ago with the discovery of a patient with mitochondrial
dysfunction. The field of mitochondrial medicine has experienced
explosive growth during the last decade. More than 50 mtDNA
mutations and several nuclear gene mutations have been
identified in affected patients. The recent development of animal
models will continue the revolution in mitochondrial medicine by
facilitating in depth studies of the molecular pathogenesis and
development of novel drug and gene therapy strategies for
mitochondrial dysfunction. As we enter the next millennium, we
can expect mitochondrial medicine to remain a dynamic and
rapidly developing field.
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1. Introduction
Mitochondrial dysfunction is increasingly recognized as an
important cause of human pathology [1^3]. The discovery of
the ¢rst patient with mitochondrial disease in 1962 started a
revolution in chemical pathology [4]. During the next decades,
large numbers of patients with biochemical and morphologi-
cal evidence of respiratory chain dysfunction were described.
In 1988, a critical break-through toward our understanding of
mitochondrial diseases came with the discovery of pathogenic
deletions and point mutations in mtDNA [5,6]. Clinical phe-
notypes correlated with the presence of speci¢c mtDNA mu-
tations, and important insights into the pathogenetic mecha-
nisms were obtained. Now, there are more than 50 disease-
causing base substitution mutations and hundreds of mtDNA
rearrangements known [3,7^9]. This brief review focuses on
recent important advances in this rapidly developing area of
mitochondrial medicine, e.g. nuclear gene mutations causing
mitochondrial diseases in man, mitochondrial involvement in
ageing and common human diseases and mitochondrial dys-
function in animal models.
2. Mitochondria and mitochondrial DNA
The ancestors of mitochondria were probably ancient bac-
teria that lived as intracellular parasites in primitive eukary-
otic cells [10]. Several rounds of reductive evolution deleted or
transposed most of the original bacterial genome to the nu-
cleus, and transformed the intracellular parasite into an or-
ganelle heavily dependent on the nucleus [10].
Mitochondria may constitute a dynamic cellular network. A
mitochondrion is composed of four compartments, i.e. the
outer membrane, the intermembrane space, the folded inner
membrane and the matrix. The respiratory chain is embedded
in the inner membrane of the mitochondrion. It produces
ATP through the process of oxidative phosphorylation. The
respiratory chain consists of V100 di¡erent proteins distrib-
uted in ¢ve respiratory chain enzyme complexes: complex I
(NADH dehydrogenase), complex II (SDH), complex III (cy-
tochrome c reductase), complex IV (COX) and complex V
(ATP synthase). Complexes I^IV constitute the electron trans-
port chain that generates a proton gradient across the inner
membrane used by complex V to drive ATP synthesis.
Nass and Nass [11] discovered mtDNA in 1963. The com-
plete sequences of mouse [12] and human mtDNA [13] were
published in 1981, pioneering subsequent achievements in ge-
nome sequencing. Mammalian mtDNA is a circular molecule
of V16 kb that is present in thousands of copies per cell [14].
Usually, all mtDNA copies are identical, referred to as homo-
plasmy. However, in some instances two or more mtDNA
types may coexist within the same cell, referred to as hetero-
plasmy. Inheritance of mtDNA is strictly maternal, and a
female harboring a heteroplasmic mtDNA mutation may
transmit widely varying levels of mutated mtDNA to her o¡-
spring.
The displacement (D-) loop region is the only long non-
coding region in mtDNA. It contains the promoters for tran-
scription of both mtDNA strands and the initiation site for
mtDNA replication [14]. Transcription produces polycistronic
transcripts corresponding to both mtDNA strands. Processing
of the primary transcripts releases the 13 mRNAs, 22 tRNAs
and two rRNAs. All 13 proteins encoded by mtDNA are key
components of the respiratory chain. Thus, mtDNA expres-
sion is critical for maintaining oxidative phosphorylation. The
vast majority of the V1000 di¡erent mitochondrial proteins
are encoded by nuclear genes. This includes all proteins
needed for mtDNA replication and transcription and for mi-
tochondrial translation, the majority of the respiratory chain
subunits, all proteins constituting the protein import machi-
nery, and those performing other metabolic functions in mi-
tochondria. Hence, mutations of nuclear genes may a¡ect a
wide variety of mitochondrial functions.
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3. Nuclear gene mutations causing mitochondrial dysfunction
The vast majority of the V100 respiratory chain subunits
are encoded by nuclear genes, and mutations in them can
a¡ect any of the ¢ve respiratory chain enzyme complexes
(Table 1). An amino acid substitution of the £avoprotein sub-
unit of SDH was found in two siblings with necrotizing ence-
phalopathy (Leigh syndrome) and complex II de¢ciency [15].
Duplication within a nuclear gene encoding the 18 kDa pro-
tein of complex I was observed in a child with severe enceph-
alopathy and complex I de¢ciency [16]. Mutations in a nuclear
gene (NDUFV1) encoding a 51 kDa complex I subunit were
found in children with leukodystrophy and myoclonus epi-
lepsy [17]. A subgroup of patients with Leigh syndrome has
COX de¢ciency and harbors mutations in the SURF1 gene
[18,19]. Studies of yeast mutants demonstrated that the
SURF1 homologue of yeast (SHY1) is required for respira-
tion, and may regulate assembly or stability of the COX holo-
enzyme [20].
Nuclear genes encode all proteins needed for maintenance
and transcription of mtDNA and all proteins needed for
translation of mitochondrial transcripts. Patients with autoso-
mal recessive, mitochondrial neurogastrointestinal encephalo-
myopathy (MNGIE), have multiple deletions of mtDNA in
muscle [21]. Mutations in the thymidine phosphorylase gene
exist in multiple MNGIE pedigrees suggesting that aberrant
thymidine metabolism leads to mtDNA instability [22]. Sev-
eral families with autosomal dominant progressive external
ophthalmoplegia (adPEO) have been identi¢ed, and responsi-
ble genes mapped to chromosomes 10q23.3^24.3 [23] and
3p14.1^21.2 [24]. Interestingly, the distribution of the multiple
mtDNA deletions is non-random in a¡ected patients, and
clonal expansion of a single type of mtDNA deletion is found
in a¡ected muscle ¢ber segments [25]. Several children with
mtDNA depletion and fatal lactic acidosis have been de-
scribed [26]. Most evidence suggests autosomal recessive in-
heritance, but no locus has yet been identi¢ed.
Mutations of the DPP1 gene are found in an X-linked
syndrome causing sensorineural hearing loss, dystonia, corti-
cal blindness and other symptoms. The DPP1 protein is ho-
mologous to the yeast Tim8, Tim9, Tim10 and Tim12 pro-
teins, which are components of the mitochondrial protein
import machinery. Thus, this syndrome is probably caused
by defective protein import, impairing respiratory chain func-
tion [27].
Patients with autosomal recessive spastic paraplegia have
mutations in the paraplegin gene, encoding a mitochondrial
protease belonging to the ATP-dependent metalloproteinase
family [28]. An increased frequency of ragged-red muscle ¢-
bers is found in a¡ected patients indicating that paraplegin
de¢ciency impairs respiratory chain function [28].
Friedreich’s ataxia is a common autosomal recessive disease
caused by an intronic triplet expansion in the frataxin gene
[29]. Clinical features include progressive gait and limb ataxia,
dysarthria and cardiomyopathy. The function of frataxin is
probably to transport iron out of the mitochondria. Muta-
tions of the yeast frataxin homologue (YFH1) cause iron ac-
cumulation in mitochondria [30]. Interestingly, excessive
amounts of mitochondrial iron will lead to increased forma-
tion of reactive oxygen species (ROS), which preferentially
attack iron-sulfur (Fe-S) cluster containing proteins such as
aconitase and the respiratory chain enzyme complexes I, II
and III in a¡ected patients [31].
4. Ageing and mitochondrial dysfunction
Several lines of correlational and genetic data implicate
mitochondrial dysfunction in the naturally occurring process
of ageing. In 1986, Miquel and Fleming [32] presented the
‘oxygen radical-mitochondrial injury hypothesis of ageing’.
It states that the raised respiration of di¡erentiated cells will
increase ROS production to levels exceeding the detoxifying
defenses. This will impair the cell’s capacity to regenerate
mitochondria and result in progressive deterioration of ATP
production. Animals with homozygous knockout of the mito-
chondrial isoform of SOD (MnSOD or Sod2) develop dilated
cardiomyopathy [33], demonstrating that impaired mitochon-
drial defense to ROS indeed has grave consequences. Iron-
sulfur containing enzymes are particularly vulnerable to
ROS attacks and, as a consequence, Sod23/3 mice develop
a de¢ciency of SDH and aconitase [33], similar to the bio-
chemical phenotype of patients with Friedreich’s ataxia.
Treatment with a SOD mimetic chemical compound increases
the life span of Sod23/3 mice dramatically and prevents car-
diomyopathy [34]. However, these treated mutant mice devel-
op a neurological phenotype, possibly due to failure of the
Table 1
Nuclear mutations a¡ecting mitochondrial biogenesis
Mutated gene Biochemical consequence Phenotype of patients Reference
Flavoprotein subunit of complex II complex II de¢ciency Leigh syndrome [15]
18 kDa complex I subunit complex I de¢ciency Severe encephalopathy [16]
51 kDa complex I subunit (NDUFV1) complex I de¢ciency leukodystrophy and myoclonus epilepsy [17]
SURF1 complex IV de¢ciency,
defective stability of complex IV
Leigh syndrome [18,19]





Unknown multiple mtDNA deletions progressive external ophthalmoplegia
(adPEO)
[23,24]
Unknown mtDNA depletion fatal infantile myopathy [26]
DPP1 defective mitochondrial protein import sensorineural hearing loss, dystonia,
cortical blindness
[27]
Paraplegin metalloproteinase de¢ciency, defective
mitochondrial protein turnover
spastic paraplegia [28]
Frataxin defective mitochondrial iron homeostasis,
complex I, II and III de¢ciency
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drug to cross the blood-brain barrier [34]. Mutations of one of
the cytoplasmic SOD isoforms (CuZnSOD or SOD1) have
been reported in familial amyotrophic lateral sclerosis, a dis-
ease with extensive loss of motor neurons [35]. Transgenic
overexpression of human SOD1 in motor neurons of Droso-
phila extends the life span of these transgenic £ies by 40% [36].
These ¢ndings suggest that antioxidant defenses, at least
under some circumstances, may determine cell survival and
life span.
Numerous reports demonstrate that deleted mtDNA accu-
mulates in certain tissues with increasing age. This may lead
to an age-related reduction in oxidative phosphorylation ca-
pacity [37]. Indeed, some studies demonstrate an age-related
reduction in respiratory chain function [38], but others ¢nd no
correlation between age and respiratory chain function [39].
Levels of deleted mtDNA in old individuals are low (6 10%),
but such low levels will not impair respiratory chain function
if the deleted mtDNA is evenly distributed. However, uneven
distribution resulting in accumulation of deleted mtDNA in
particular cells may lead to a mosaic respiratory chain de¢-
ciency and pathology.
In vitro cell cultures of cybrids between human cells lacking
mtDNA (b0 cells) [40] and mitochondria from young and old
subjects demonstrate respiratory chain de¢ciency in cybrids
containing mitochondria from older subjects [41]. In contrast,
other cybrid experiments show that nuclear rather than
mtDNA mutations are responsible for the observed age-re-
lated reduction of oxidative phosphorylation [42].
Genetic studies suggest that respiratory chain function may
regulate life span in the worm Caenorhabditis elegans. The
mev-1 mutant is hypersensitive to increased oxygen concen-
trations, and its life span is dramatically decreased in response
to high oxygen [43]. The mev-1 mutation a¡ects a SDH sub-
unit and severely impairs electron transport [43]. Mutations of
the clk-1 gene moderately extend life span in C. elegans [44]
and the yeast homologue of this gene (Coq7) has been found
to be involved in di¡erent metabolic pathways, e.g. CoQ syn-
thesis [45]. There are dual roles for CoQ in vivo; it is an
essential component for respiratory chain electron transport
and also functions as a lipid soluble antioxidant. It is possible
that the decreased CoQ synthesis in the clk-1 mutants slows
the metabolic rate in C. elegans and that this explains the
prolonged life span [45]. It has also been speculated that the
clk-1 mutation leads to the disappearance of CoQ semiqui-
none, which has a prooxidant activity, and that loss of this
compound explains the extended life span in mutant worms
[46]. Interestingly, a clk-1 mutation combined with a daf-2
mutation, a¡ecting another genetic pathway, dramatically
prolongs the life span of C. elegans demonstrating that regu-
lation of longevity is polygenic [45].
5. Animal models for mitochondrial diseases
The genetics of mitochondrial disorders has revealed much
about the disease mechanisms. Recently, new insights into the
pathophysiology of these disorders have been obtained from
animal models.
An animal model for mitochondrial diseases was generated
by knockout of the Ant1 gene. Homozygous knockout ani-
mals (Ant3/3) are viable, but exhibit increased levels of blood
lactate, mitochondrial myopathy and hypertrophic cardiomy-
opathy with mitochondrial proliferation [47].
Disruption of theTfam gene demonstrated that this nuclear-
encoded protein is necessary for mtDNA maintenance in vivo
[48]. Homozygous Tfam knockouts die in midgestation and
have a mutant phenotype with lack of heart, delayed neural
development and absence of optic discs. The mutant embryos
lack mtDNA, and have a severe respiratory chain de¢ciency
with massive accumulation of morphologically abnormal mi-
tochondria [48]. Recently, the cre-loxP conditional knockout
strategy was used to selectively disrupt Tfam in heart and
skeletal muscle [49]. These mutant animals develop dilated
mitochondrial cardiomyopathy with biochemical, morpholog-
ical and physiological features that are similar to the ¢ndings
in mtDNA deletion diseases [49].
Heteroplasmic mice containing two di¡erent types of
mtDNA were created by fusing cytoplasts from oocytes of
one mouse strain with fertilized one-cell stage embryos from
another [50]. Mating of these heteroplasmic animals demon-
strates that the segregation of the two types of mtDNA is
determined by random genetic drift in the female germline
[50]. Directional selection with increasing age is noted in adult
animals; one type of mtDNA increased in liver and kidney,
whereas the other type of mtDNA increased in spleen and
blood [51]. Introducing pathogenic mtDNA mutations into
mice remains unaccomplished.
A novel method for producing animal models of mitochon-
drial myopathy, recently described by Clark et al. [52], may
provide a valuable model for treatment trials. Human myo-
blasts containing di¡erent pathogenic mtDNA mutations were
transplanted into irradiated muscle of severe combined immu-
node¢ciency (SCID) mice. Injected myoblasts expressed hu-
man muscle markers and were also innervated.
Recent observations using animal models suggest the pos-
sibility of introducing mtDNA mutations into the animal
germline. This may result in a better understanding of how
mtDNA mutations a¡ect energy production and will provide
insights into the role such defects play in the pathophysiology
of mitochondrial disorders.
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